吴晶
- 教师名称：吴晶
- 教师拼音名称：WuJing
- 性别：女
- 职务：党委书记
- 学科：卫生事业与药事管理
- 职称：教授
其他联系方式
- 通讯/办公地址：
- 移动电话：
- 邮箱：
- Do machine learning approaches perform better than regression models in mapping studies? A systematic review. Value Health. 2025
- The generic version of China Health Related Outcomes Measures (CHROME-G): Psychometric testing and comparative performance with the EQ-5D-5L and SF-6Dv2 among the Chinese general population. BMC Public Health. 2024
- Is the Use of Unanchored Matching-Adjusted Indirect Comparison Always uperior to Naïve Indirect Comparison on Survival Outcomes? A Simulation Study. Applied Health Economics and Health Policy. 2025
- Efficiency must not compromise trustworthiness in rating certainty and formulating recommendations in AI era. BMJ. 2025
- Efficacy, Safety, and Treatment Burden of Aflibercept 2 mg and Ranibizumab in Retinal Vein Occlusion: A Systematic Review and Meta-Analysis. Ophthalmol Ther. 2024
- Enhancing the Interpretation of Continuous Outcomes and Subgroup Analyses in Systematic Reviews. JAMA Pediatr. 2024
- Impact of China’s national volume-based procurement on drug procurement price, volume, and expenditure: an interrupted time series analysis in Tianjin. International Journal of Health Policy and Management. 2023
- Incorporating absolute effects to enrich interpretation of findings from meta-analyses. The Lancet Oncology. 2023
- Diversity when interpreting evidence in network meta-analyses (NMAs) on similar topics: an example case of NMAs on diabetic macular oedema. Systematic Reviews. 2023
- Can case-based payment contain healthcare costs? - A curious case from China. Soc Sci Med. 2022
- Cost Effectiveness of the First-in-Class ARNI (Sacubitril/Valsartan) for the Treatment of Essential Hypertension in a Chinese Setting. Pharmacoeconomics. 2022
- Policy Updates on Access to and Affordability of Innovative Medicines in China. Value Health Reg Issues. 2022
- Estimation of the cost-effective threshold of a quality-adjusted life year in China based on the value of statistical life. Eur J Health Econ. 2022
- China Health Related Outcomes Measures (CHROME): Development of a New Generic Preference-Based Measure for the Chinese Population. Pharmacoeconomics. 2022
- How Do Treatment Preferences of Patients With Cancer Compare With Those of Oncologists and Family Members? Evidence From a Discrete Choice Experiment in China. Value Health. 2022